Skip to main content

Day: April 17, 2020

Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products

TORONTO, April 17, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has engaged Complete Phytochemical Solutions, LLC., an internationally-recognized company specializing in unique and complex analyses and formulation development of phytochemicals, to advance the Company’s research and development initiatives of psilocybin-based products for the pharmaceutical market.“Revive has an intellectual property portfolio of psilocybin-based formulations ready to advance to the next stages of clinical development and with our newly-established relationship with Complete Phytochemical Solutions they will bring a wealth of product formulation and testing...

Continue reading

Preclinical Study Showing Beneficial Effects of Cymerus™ MSCs in Acute Respiratory Distress Syndrome Accepted for Publication in Leading Peer-Reviewed Journal

MELBOURNE, Australia, April 17, 2020 (GLOBE NEWSWIRE) — Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that a scientific paper describing the use of Cymerus™ mesenchymal stem cells (MSCs) in a model of Acute Respiratory Distress Syndrome (ARDS) has been accepted for publication in the American Journal of Respiratory and Critical Care Medicine (AJRCCM).1 The AJRCCM, commonly known as “The Blue Journal”, is widely regarded as the foremost peer-reviewed journal in the field of respiratory and critical care medicine.BackgroundThe study was conducted in 14 sheep with severe ARDS supported by extracorporeal membrane oxygenation (ECMO), which were given an endobronchial infusion of either Cymerus MSCs (n=7) or placebo (n=7). Animals were monitored...

Continue reading

Apollo Commercial Real Estate Finance, Inc. Announces Dates for First Quarter Earnings Release and Conference Call

NEW YORK, April 17, 2020 (GLOBE NEWSWIRE) — Apollo Commercial Real Estate Finance, Inc. (the “Company” or “ARI”) (NYSE:ARI), today announced the Company will hold a conference call to review its first quarter 2020 financial results on Friday, May 8, 2020 at 9:00 a.m. Eastern Time.  The Company’s first quarter financial results will be released after the market closes on Thursday, May 7, 2020.  During the conference call, Company officers will review first quarter 2020 performance, discuss recent events and conduct a question-and-answer period.Teleconference Details:Members of the public who are interested in participating in the Company’s first quarter 2020 earnings teleconference call should dial from the U.S., (877) 331-6553, or from outside the U.S., (760) 666-3769, shortly before 9:00 a.m. and reference the Apollo Commercial...

Continue reading

National General Holdings Corp. to Announce 2020 First Quarter Results on April 29, 2020

NEW YORK, April 17, 2020 (GLOBE NEWSWIRE) — National General Holdings Corp. (NASDAQ:NGHC) announced today that it plans to release 2020 first quarter results after the market closes on Wednesday, April 29, 2020. At 9:00 AM ET on Thursday, April 30, 2020, Chief Executive Officer Barry Karfunkel and Chief Financial Officer Mike Weiner will review results and discuss business conditions via a conference call that may be accessed as follows:A replay of the conference call will be accessible from 2:00 PM ET on Thursday, April 30, 2020 to 11:59 PM ET on Thursday, May 14, 2020 by dialing either 800-332-6854 (toll-free) within the U.S. or 973-528-0005 outside the U.S. and entering passcode 929313. In addition, a replay of the webcast can also be retrieved at http://ir.nationalgeneral.com/events-and-presentations.About National General Holdings...

Continue reading

OliX Pharmaceuticals Expands Scientific Advisory Board with Addition of Leading Liver Experts

SUWON, Republic of Korea, April 17, 2020 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a key player in the development of RNAi therapeutics, today announced the appointment of Dr. Gordon Jiang, Dr. Aaron Hakim and Dr. Yury V. Popov to its Scientific Advisory Board (SAB). The SAB will work with OliX Pharmaceuticals executive team to refine the emerging pipeline as well as clinical strategy for the company’s assets.“We are pleased to welcome Dr. Jiang, Dr. Hakim and Dr. Popov, renowned liver disease experts, to OliX Pharmaceuticals’ Scientific Advisory Board,” said Dong-Ki Lee, Ph.D., founder and Chief Executive Officer of OliX Pharmaceuticals. “Their depth of scientific expertise will be critical as we enter a pivotal phase in advancing the Company’s liver fibrosis pipeline.”Backgrounds of Newly Appointed Scientific...

Continue reading

New Stifel Survey Examines Impact of COVID-19 on Global Technology Community

ST. LOUIS, April 17, 2020 (GLOBE NEWSWIRE) — A new Stifel Financial Corp. (NYSE: SF) survey of nearly 300 technology executives, entrepreneurs, and private equity (PE) and venture capital (VC) investors finds most expect the COVID-19 crisis to have a lengthy impact on business operations, leading to a U-shaped economic recession. At the same time, the survey indicates that a majority of companies appear to have sufficient liquidity to weather the storm and potentially eye add-on acquisitions.Key survey highlights include:The majority of PE/VC respondents (62%) expect to see a business impact from COVID-19 on their portfolio companies for more than six months, while nearly half of tech executives/entrepreneurs (46%) are also planning for disruption lasting at least half a year. Most (55% of executives/entrepreneurs and 65% of PE/VC...

Continue reading

IZEA Announces Launch of BrandGraph® Trends

Orlando, Florida, April 17, 2020 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), operator of IZEAx®, the premier online marketplace connecting brands and publishers with influential content creators, today announced the launch of BrandGraph® Trends. BrandGraph Trends is designed to help marketers identify, compare and contrast momentum among brands, topics, and concepts in social media. Powered by IZEA’s proprietary content classification engine, BrandGraph Trends allows marketers to benchmark any keyword against a brand or groups of brands in a general industry or specific category.For example:Compare mentions of Coronavirus against content mentioning Purell.Compare content engagement rate of Purell against engagement rate of Lysol.Compare sentiment of Lysol against sentiment of all the brands in the household cleaner category.Compare...

Continue reading

Todos Medical Appoints Dr. Lauren Chung to its Board of Directors

 Receives valuation of Alzheimer’s disease blood diagnostic LymPro Test Retains Donohoe Advisors to assist with Nasdaq CM™ listing processREHOVOT, Israel, SINGAPORE and NEW YORK, NY, April 17, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE —Todos Medical Ltd. (OTCQB: TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders as well as point-of-care and lab-based tests for COVID-19, announces the appointment of Lauren Chung, Ph.D. to its Board of Directors. This appointment increases the size of the Todos Medical Board to 7 Directors, including 2 independent Directors.  Dr. Chung has been named lead independent Director, and will serve as Chair of both the Compensation Committee and the Nomination and Governance Committee.Todos Medical...

Continue reading

Deveron Announces Closing of Second Tranche of Private Placement

TORONTO, April 17, 2020 (GLOBE NEWSWIRE) — Deveron UAS Corp. (CSE: DVR) (“Deveron” or the “Company”) a leading agriculture digital services and insights provider in North America is pleased to announce the closing of a second and final tranche (see press release dated, April 7, 2020) of a non-brokered private placement (the “Offering”) of units (“Units”).  This final tranche was completed at a price of $0.10 per Unit for gross proceeds of $700,000 and a total of 7,000,000 Units issued.  Combined with the first tranche, Deveron issued a total of 13,550,000 Units for aggregate gross proceeds of $1,355,000 in connection with the Offering.“We are pleased to see the additional interest in our growth plan and strategy,” commented David MacMillan, Deveron’s President and CEO.  “With this investment round now complete, we are excited to...

Continue reading

Aleafia Health Provides Update on Strategic Growth Initiatives

Successful transition to virtual clinic services with 3,300 remote patient consultations completed since March 16, 2020Last-mile home delivery for medical cannabis products launching next weekPort Perry outdoor cultivation site is plant ready for 2020 seasonCannabis production started at newly licensed Niagara FacilityCompany preparing to commence operations at Paris Production Facility’s expansionTORONTO, April 17, 2020 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF) (“Aleafia Health” or the “Company”) is pleased to provide a comprehensive corporate update on strategic growth initiatives.“Aleafia Health’s focus on disciplined, sustainable and scalable growth is more important now than ever with the launch of two major initiatives to adapt to patients’ needs during COVID-19,” said Aleafia Health CEO Geoffrey Benic....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.